We are live on ! Find out more
SCM

Soleus Capital Management Portfolio holdings

AUM $2.47B
1-Year Est. Return 115.63%
This Fund
S&P 500
This Quarter Est. Return
+5.02%
1 Year Est. Return
+115.63%
3 Year Est. Return
+435.52%
5 Year Est. Return
+604.31%
10 Year Est. Return
–
AUM
$650M
AUM Growth
+$95.3M
Cap. Flow
+$75.6M
Cap. Flow %
11.63%
Top 10 Hldgs %
57.73%
Holding
90
New
18
Increased
17
Reduced
23
Closed
25

Top Buys

Rank Stock Value
1
NPCE icon
Neuropace
NPCE
+$32.1M
2
FOCL
EDAP TMS S.A.
FOCL
+$16.9M
3
CCCC icon
C4 Therapeutics
CCCC
+$14.6M
4
NVCR icon
NovoCure
NVCR
+$14.3M
5
NEO icon
NeoGenomics
NEO
+$13.6M

Top Sells

Rank Stock Value
1
BCAB icon
BioAtla
BCAB
+$17.4M
2
XENE icon
Xenon Pharmaceuticals
XENE
+$8.74M
3
KRYS icon
Krystal Biotech
KRYS
+$6.93M
4
DMRA
Damora Therapeutics, Inc. Ordinary Shares
DMRA
+$5.31M
5
FLXN
Flexion Therapeutics, Inc.
FLXN
+$4.68M

Sector Composition

Rank Sector Weight
1 Healthcare 90.8%
2 Consumer Staples 2.41%
3 Financials 0.49%
4 Real Estate 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BCAB icon
1
BioAtla
BCAB
$5.59M
$118M 18.21%
55,885
-7,702
-12% -$17.4M
EPIX
2
DELISTED
ESSA Pharma
EPIX
$63.9M 9.83%
2,238,104
+168,052
+8% +$4.88M
CCCC icon
3
C4 Therapeutics
CCCC
$376M
$32.9M 5.07%
870,758
+406,690
+88% +$14.6M
NPCE icon
4
Neuropace
NPCE
$505M
$32.9M 5.06%
+1,384,387
New +$32.1M
THER
5
DELISTED
THERATECHNOLOGIES INC COM
THER
$27.3M 4.19%
7,028,096
+76,749
+1% +$298K
LNTH icon
6
Lantheus
LNTH
$6.82B
$25.3M 3.88%
913,697
-53,675
-6% -$1.23M
NVCR icon
7
NovoCure
NVCR
$2.04B
$22M 3.38%
98,975
+73,650
+291% +$14.3M
FOCL
8
EDAP TMS S.A.
FOCL
$226M
$18.3M 2.81%
2,576,401
+2,326,835
+932% +$16.9M
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$17.7M 2.73%
2,808,343
-572,636
-17% -$3.69M
CRSP icon
10
CRISPR Therapeutics
CRSP
$4.58B
$16.7M 2.57%
+103,114
New +$12.5M
NEO icon
11
NeoGenomics
NEO
$1.81B
$15.9M 2.45%
352,007
+306,056
+666% +$13.6M
SKIN icon
12
SkinHealth Systems
SKIN
$94.9M
$15.7M 2.41%
934,316
+13,600
+1% +$186K
SRDX
13
DELISTED
Surmodics
SRDX
$15.1M 2.32%
278,404
+124,129
+80% +$6.81M
AZN icon
14
AstraZeneca
AZN
$263B
$15M 2.3%
125,073
-4,150
-3% -$455K
IRMD icon
15
iRadimed
IRMD
$1.21B
$14.6M 2.25%
497,179
+15,109
+3% +$416K
ITMR
16
DELISTED
Itamar Medical Ltd. American Depository Shares
ITMR
$12.5M 1.92%
530,839
+260,759
+97% +$5.82M
CVRX icon
17
CVRx
CVRX
$126M
$11.9M 1.84%
+426,394
New +$11.9M
SIEN
18
DELISTED
Sientra, Inc.
SIEN
$11.6M 1.79%
146,156
+108,366
+287% +$7.7M
NTRA icon
19
Natera
NTRA
$37.5B
$11.6M 1.78%
101,839
+23,600
+30% +$2.41M
HOWL icon
20
Werewolf Therapeutics
HOWL
$20.8M
$9.83M 1.51%
+563,396
New +$7.72M
PCVX icon
21
Vaxcyte
PCVX
$7.89B
$8.46M 1.3%
375,650
+82,000
+28% +$1.68M
EOLS icon
22
Evolus
EOLS
$394M
$7.34M 1.13%
+580,000
New +$6.38M
INBX
23
DELISTED
Inhibrx, Inc. Common Stock
INBX
$6.68M 1.03%
242,789
-158,704
-40% -$3.3M
EDIT icon
24
Editas Medicine
EDIT
$399M
$5.42M 0.83%
+95,600
New +$3.53M
CUTR
25
DELISTED
Cutera, Inc.
CUTR
$5.05M 0.78%
102,980
-17,020
-14% -$625K
1
2 3 4

Similar funds

TW
Trajan Wealth Scottsdale, Arizona $2.48B AUM 17.44% 1-Year Est. Return
JC
JB Capital Wethersfield, Connecticut $2.48B AUM 22.31% 1-Year Est. Return
M
Mirova Paris, France $2.46B AUM 11.42% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $2.48B AUM 72.25% 1-Year Est. Return
BW
BIP Wealth Atlanta, Georgia $2.46B AUM 14.38% 1-Year Est. Return
BL
Balentine LLC Atlanta, Georgia $2.48B AUM 17.44% 1-Year Est. Return
FFA
First Foundation Advisors Irvine, California $2.48B AUM 18.56% 1-Year Est. Return
GWM
Greenwich Wealth Management Greenwich, Connecticut $2.45B AUM 39.53% 1-Year Est. Return

Soleus Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Soleus Capital Management held 90 positions worth $650M, up 17% from $555M the previous quarter. Its ten largest holdings account for 58% of the portfolio.

Soleus Capital Management deployed $75.6M of net new capital in Q2 2021, opening 18 new positions and adding to 17 existing holdings. Its largest new stake was Neuropace: 1,384,387 shares worth $32.9M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 91% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was BioAtla, an estimated $17.4M trimmed.

  • Soleus Capital Management's largest Q2 2021 buy was Neuropace: 1,384,387 shares worth $32.9M.
  • Soleus Capital Management added most to EDAP TMS S.A. in Q2 2021, an estimated $16.9M increase.
  • Soleus Capital Management's biggest Q2 2021 reduction was BioAtla, cutting an estimated $17.4M.
  • Soleus Capital Management fully exited Flexion Therapeutics, Inc. in Q2 2021, selling an estimated $4.68M.
  • Soleus Capital Management's ten largest holdings make up 58% of its $650M portfolio in Q2 2021.
  • Soleus Capital Management opened 18 new positions and closed 25 in Q2 2021.
  • Soleus Capital Management's portfolio value rose 17% quarter-over-quarter to $650M.

Based on Soleus Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.